current state
page analyst certif import disclosur
new coronaviru made presenc known global
data adapt cdc gov guggenheim secur
page analyst certif import disclosur
coronavirus respons sar mer on-going outbreak chang live know
coronavirus arent new discov earliest discoveri viru caus bronchiti chicken two virus
famili discov human caus common cold symptom human caus mild respiratori infect symptom similar
common cold infect type develop lethal pneumonia patient cow pig coronaviru
typic caus intestin diseas manifest diarrhea bird caus respiratori ill
increas interact human wildlif increas risk zoonot virus evolv enhanc virul point
sar viru emerg china bat move civet final human year later mer cov also emerg bat transfer
dromedari camel middl east human new coronaviru respons caus emerg china way
anim live market declar pandem march
bat seem natur reservoir current coronaviru per zhou et al howev viru seem mutat along
way anim specul transmit civet pangolin racoon dog recogn intermedi host zoonot
transmiss bat human
intermedi host answer remain unknown sinc viru fairli new appear
emerg hcov time
adapt forni et al guggenheim secur
page analyst certif import disclosur
differ type coronaviru
differ type cov infect human mammal bird
categor differ sub-typ alpha beta gamma delta base phylogenet
alpha beta sub-typ infect mammal
deltacoronavirus infect mammal avian speci
date type coronaviru known infect human four low pathogen coronavirus
endem human includ
common human coronavirus typic caus mild symptom new type coronavirus shown
sever symptom lethal note novel virus develop anim adapt infect
human develop new virul trait caus sever symptom increas lethal rate date
therapeut vaccin approv human-infect coronavirus
classif coronavirus
three recent exampl cov
mers-cov coronaviru caus middl east respiratori syndrom mer
sars-cov coronaviru caus sever acut respiratori syndrom sar
novel coronaviru caus coronaviru diseas
multitud cov result inher genom divers
high divers cov attribut viral trait
potenti high mutat rate associ rna replic gener estim rang
case sars-cov rate chang depend environmental/stress pressur
recombin frequenc within cov famili high mix infect like result
discontinu rna transcript recombin viral genom subgenom replic
iii sinc cov largest rna virus increas opportun chang room
modif allow virus rapidli adapt novel host via plastic surfac glycoprotein
toler high rate mutat ecolog nich tissu tropism even gener novel cov
adapt li guggenheim secur
page analyst certif import disclosur
coronavirus part coronavirida famili within order nidoviral
envelop positive- strand rna virus genom
make largest known rna virus
polycistron genom organ mean one mrna encod
coronavirus also use uniqu transcript mechan produc set subgenom sg
mrna sgmrna use express open read frame orf
downstream replicas orf encod structur accessori protein basic
coronaviru skill pack lot inform tini capsid
speak capsid coronavirus genom contain within helic
capsid surround envelop
coronavirus approxim diamet
helic capsid form nucleocapsid protein
envelop compos three structur protein envelop protein membran
protein involv membran assembl spike protein mediat
viral entri cell coronavirus also encod envelope-associ hemagglutinin-
esteras protein bind sialic acid host glycoprotein thought promot viral
entri host cell viral spread mucosa
protein form long project envelop viru give viru crown-lik
appear henc name coronaviru corona latin mean crown
spike protein consist three segment short intracellular tail larg ectodomain
ectodomain contain two unit receptor-bind subunit subunit bind host
receptor mediat viral attach ii membran fusion subunit subunit fuse
viral host membran allow viral genom enter host cell
coronaviru structur top
ectodomain spike glycoprotein bottom
adapt wild et al holm li guggenheim secur
page analyst certif import disclosur
skeleton
genom resembl typic cov genom detail earlier singl
imag
isol clinic sampl
viru belong group betacoronavirus also includ batsarslik batsl
sarscov merscov nucleotid sequenc homolog new viru ident bat coronaviru
isol close relat batslcov batslcov
distantli relat sarscov
viru spiki capsid first point contact host cell
virion diamet compos viru four structur protein spike envelop
membran nucleocapsid like coronavirus detail previous protein form physic
shell hold rna genom protein form viral envelop
amino acid long spike protein believ protein help viru latch onto host
cell membran start process infect detail next slide import perspect
virus-host cell receptor bind tissu tropism pathogenesi
spike protein rbd furin cleavag site enabl becom zoonot viru
one spread anim peopl
coronaviruss receptor bind domain rbd region bind specif receptor host cell
subunit variabl part viral genom rbd mutat circul strain confer
addit structur stabil infect protein
subunit intern fusion peptid ifp enabl viral entri furin cleavag sequenc
prrars|v activ presenc proteas furin addit lead prolin prra
region result o-link glycosyl around site make uniqu new viru
side note close relat bat cov furin cleavag site noteworthi
insert site ha glycoprotein highli pathogen avian influenza virus contribut higher
pathogen enhanc cellular tropism
coutard et al specul gain-of-funct furin cleavag site allow bat cov gain abil
infect human attack respiratori system specif furin highli express lung liver
small intestin new viru possibl exploit convertas activ spike protein per research
group interestingli site process viral egress case mers-cov endocytosi sars-
structur spike protein
adapt nih gov wrapp et al guggenheim secur
page analyst certif import disclosur
latch onto angiotensin-convert enzym
receptor gain entri cell
bind receptor tightli compar sars-cov
cov receptor interact key determin regul host rang cross-speci transmiss tissu tropism
use dens glycosyl spike protein enter cell trigger bind
subunit receptor
studi identifi host cellular receptor sars-cov turn receptor
also entri point viru also use host proteas prime entri cell cut open
spike protein expos fusion peptid
subunit rbd allow viru directli bind peptidas domain pd subunit thought
play role membran fusion henc spike critic attach viru host cell surfac
also fusion viral host cell membran allow infect start
addit receptor activ dimer form henc result two peptidas domain abl bind two
share amino acid ident sars-cov cov respect
wrapp et al show rbd differ sars-cov rbd hotspot variant
bind site enabl tighter complex format result higher bind affin
compar sars-cov enhanc affin receptor may critic factor increas viru
infect human-to-human transmiss vs cov though yet proven
knowledg receptor import perspect potenti antivir intervent target
exampl inhibitor use decoy ligands/antibodi spike serum
convalesc sar patient neutral entri later
anoth door cellular entri
wang et al note could also use receptor/basigin invad host cell
cell express includ alveolar type cell cell respons surfact biosynthesi self-renew
lung esophagu upper stratifi epitheli cell lymphocyt within mucosa oral caviti epitheli cell
tongu absorpt enterocyt ileum colon vulner intestin epitheli cell cholangiocyt epitheli
cell bile duct myocardi cell kidney proxim tubul cell bladder urotheli cell
variat red
superimpos
sars-cov rbd white
adapt wrapp et al guggenheim secur
page analyst certif import disclosur
summari life-cycle
initi attach host cell begin s-protein mediat interact host receptor
protein split two sub-unit mediat distinct task attach entri respect
interact host receptor promot receptor mediat endocytosi allow viral
life-cycle sars-cov
entri host cell
viral attach entri endosom establish viru must gain access host begin
infect occur first cleavag separ rbd fusion domain protein viral
attach follow second cleavag site expos fusion peptid fp split
intern fusion peptid ifp believ fp ifp particip viral entri process
gener cov cleavag allow fp insert membran acidifi endosom
two heptad repeat join form antiparallel six helix bundl format promot mix viral host
membran result fusion releas viral genom cytosol
viral modul host innat immun respons
importantli dampen type ifn pathway delay immun recognit
upon infect cell genom direct synthesi two long polyprotein includ machineri
viru need replic new virus explain earlier protein includ replication/ transcript
complex make rna sever structur protein construct new virion two proteas
proteas cut polyprotein mention function piec
main proteas mpro
inhibitor
shown blue
proteas main proteas mpro also refer proteas structur
enzym dimer two ident subunit togeth form two activ site proteas also peptide-lik
inhibitor bound activ site shown figur right
inhibit mpro could potenti help inhibit viral replic
adapt stadler et al protein data bank pdb guggenheim secur
page analyst certif import disclosur
summari life-cycle contd
knowledg life-cycle fulli elucid howev histor know cov
follow replic viral particles/genom subgenom rna synthesi viral structur protein
 translat insert endoplasm reticulum
life-cycle sars-cov
protein-protein interact cov assembl driven protein addit protein
express produc viral envelop protein enhanc virus-lik particl format protein
requir assembl incorpor virion critic step interact protein
er-golgi intermedi compart
move along secretori pathway er-golgi intermedi compart viral genom
encapsid protein bud membran contain viral structur protein form matur virion
virion assembl transport cell surfac vesicl releas exocytosi
report sever cov protein unincorpor viral particl reach cell surfac
enabl cell-cel fusion infect cell adjac uninfect cell result format
giant multinucl cell allow viru infect addit cell undetect neutral antibodi
adapt stadler et al guggenheim secur
page analyst certif import disclosur
potenti mechan ifn downregul
modul host innat immun respons
recent report suggest cov gener adapt evad
immun system dampen immun respons could partial explain
prolong incub period day vs season flu day share
genu thought escap immun system way similar
deploy sars-cov mers-cov interfer viral rna sens ii inhibit
type interferon ifn recognit signal iii delaying/dampen
activ downstream ifn/ifnar total affect adapt immun activ
group research univers chicago collabor recent identifi
newli map protein call viru protein conserv among
coronavirus one ident one sars-cov
essenti viru life-cycle virul recent thought
direct particip viral replic new studi elucid differ role host
immun respons modul enabl viral replic import note earli
studi inhibitor sars-cov demonstr slow
viral replic research suggest protein could novel target
drug develop
gordon et al map viral-host protein-protein interactom illustr sever viral protein impact host innat immun respons
found interact ifn pathway also modul nfkb inflammatori signal modul
ifn type respons whilst antagon host ifn signal addit viral protein possibl suppress host stress granul shut
translat target essenti antivir stress granul protein induc innat immun respons multipl mechan
granul typic induc upon recognit viral dsrna inhibit highlight pathway new repurpos drug rapamycin
inhibit mtor reduc mer infect vitro could explor antivir intervent
could also potenti modul host adapt immun respons
prolong persist viru may help exacerb inflammatori respons could lead immun exhaust immun suppress per
adapt immun evas strategi well studi present parallel could cautious drawn mers-cov infect
macrophag dendrit cell viru shown downregul antigen present via mhc class mhc class ii result markedli
adapt prompetchara et al guggenheim secur
page analyst certif import disclosur
predominantli spread respiratori transmiss
main rout transmiss via respiratori droplet and/or contact far abl tell/read evid
aerosol/airborn transmiss viru known remain stabl aerosol variou surfac hours-day
report report detect viru fece confirm patient china us suggest possibl fecal-or transmiss remain
unclear whether eat virus-contamin food could led infect and/or transmiss risk viral transmiss blood transfus present
matern fetal infect also appear possibl base report posit mother birth newborn also test posit viral nucleic acid
birth
estim
reproduct number scale defin infect viru averag number peopl one infect person
infect complet non-immun popul
put thing perspect sar mer season flu measl respect
earli data first case wuhan suggest
worri viru mutat pandem report dont suggest
accord who-china mission report signific mutat viru observ time/across geographi whole
genom sequenc strain isol patient differ locat symptom onset dec feb show homolog
interestingli grubaugh et al detail although rna virus highli prone accumul mutat everi copi cycl
intrins error-pron rna polymeras replic stringent evolutionari constraint dont allow unless mutat give
epidemiolog select advantag term transmiss virul author think unlik viral adapt human result
newer potenti danger strain
line thought also support latest on-going studi research note viru thu far maintain overal fit exhibit
genet differ us wuhan strain could attribut viru exonucleas proofread machineri
help reduc error mutat rate also suggest scientist potenti vaccin would singl vaccin confer durabl
long-term immun unlik annual vaccin need influenza
howev wed highlight tang et al studi genom found new strain viru evolv two major type
strain defin two differ tightli link although strain preval two predomin earli
day outbreak wuhan frequenc decreas jan research group specul strain might aggress spread
quickli human intervent like place sever select pressur comparison strain evolutionarili older ancestr less
aggress may increas rel frequenc due rel weaker select pressur per group
page analyst certif import disclosur
clinic manifest rang mild sever acut
incub period estim rang day median
guidanc estim day symptom appear averag day infect
includ mild respiratori symptom fever
sign symptom
clinic symptom similar sar mer fever fatigu
respiratori symptom sputum product dri cough short breath sore throat nasal
congest other headach myalgia arthralgia chill nausea diarrhea hemoptysi
conjunctiv congest case digest symptom seem becom pronounc
sever diseas increas
recent report show lymphopenia cytokin releas syndrom also import
clinic featur patient sever infect
import note base hospit patient data posit case mild-
moder recov sever diseas critic case
accord who-china report sever fatal rate reportedli milder
sar mer
note mortal rate world-wide caus
multi-organ failur especi elderli peopl underli health condit
hypertens cardiovascular diseas cancer diabet children seem much milder
diseas adult scientist current know
per cdc clinic present variabl patient experienc mean time
day ill onset hospit admiss pneumonia subset patient
median time day symptom onset ard although clinic deterior may seen
second week ill patient develop sever fatal
around patient hospit sever symptom and/or pneumonia requir
chest ct year old patient
day onset symptom show
ground glass opac lung
chest ct year old patient
day onset symptom treatment
oxygen therapi
chest ct left patient
fever day ground-glass opac
pneumonia right patient fever
day ground-glass opac earli pneumonia
adapt wang et al ai et al guggenheim secur
page analyst certif import disclosur
clinic cours immun respons
retrospect studi patient zhou et al found older age d-dimer level hospit blood protein linger
around blood clot degrad high sequenti organ failur assess sofa score risk factor associ poor prognosi
increas odd in-hospit death
wed highlight studi surviv patient significantli higher level baselin lymphocyt vs non-survivor lymphocyt count
lowest day onset ill improv hospit non-survivor sever lymphopenia death latter group also
elev level d-dimer high-sensit cardiac troponin increas rapidli day diseas onset serum ferritin lactat
dehydrogenas ldh throughout clinic cours note ldh increas survivor non-survivor earli stage sick
decreas day survivor
survivor median time ill onset fever day median durat day cough day median durat day
dyspnea day median durat day sepsi day ard day discharg day acut cardiac kidney injuri
secondari infect develop follow sepsi ard patient
non-survivor median time ill onset fever day median durat day cough day median durat day
dyspnea day median durat day sepsi day ard day death day acut cardiac kidney injuri
secondari infect develop follow sepsi ard patient
clinic cours major symptom outcom patient admit hospit
page analyst certif import disclosur
potenti patholog mechan believ viral replic immun
hyperact pulmonari destruct
potenti host immun respons elicit viru cellular
molecular patholog present well studi hypothes
consist three phase viral replic immun hyperact
lung diseas caus diffus alveolar damag cilia shed
epitheli cell prolifer increas macrophag produc
characterist pulmonari ground glass opac chest ct
diseas could also accompani lymphopenia
hemophagocytosi could result sever
patient report high level proinflammatori cytokin includ
g-csf tnf increas
level immun regulatori molecul decreas level multipl
cytokin peripher blood cell note sever diseas
patient may help predict progress pneumonia
kick viral sepsi inflammatory-induc lung injuri
may lead complic pneumon ard respiratori
failur shock organ failur potenti death
case co-infect influenza viru also report
viral load shed
latest report document high viral load earli phase diseas peak around day post symptom onset patient copies/ml
throat swab/sputum sampl indic patient could infecti time period could also transmit viru
asymptomat anoth studi higher viral load detect nose throat also lay emphasi find viral load
asymptomat patient evalu similar symptomat patient viral load also correl age older patient low immun
high express wors outcom
viral shed report last day survivor median durat day fecal sampl patient prolong
presenc rna studi report posit sampl day respiratori sampl becam neg patient
adapt prompetchara et al guggenheim secur
page analyst certif import disclosur
uptick number test come field
sever diagnost test fda-approv emerg use author eua perform diagnosi covid-
full genom viru publish year jan group german scientist develop refin first rt-pcr-base diagnost
protocol target viral gene uniqu newli discov viru specif test detect presenc envelop gene
gene enzym rna-depend rna polymeras test report high analyt sensit
protocol sinc recommend detect viru clinic swab sampl nose throat take hour
laboratori obtain result method sydney lab use test result confirm whole genom sequenc viral cultur
march fda approv eua dhr subsidiari cepheid rt-pcr base cepheid xpert xpress test provid result
minut
fda-issu test diagnos viral infect biotech biofir defens primerdesign ltd abbott molecular roch
molecular system amongst other list
current fda believ diagnos symptomat patient nasal swab front nose rather depth nasal caviti
accept would provid comfort patient sampl collect could possibl encourag self collect specimen simpler
swab
test develop
rheonix corpor seek eua fda fulli autom microfluid system-bas diagnost assay
research use rt-pcr test develop cdc target sequenc gene along rna-depend rna polymeras gene
anoth research use sherlock protocol develop mcgovern institut use synthet rna fragment
rna guid recogn two signatur test use paper strip turnaround time hour
group taiwanes research aim identifi antibodi could potenti use diagnosi could reportedli provid
result minut
heat biolog univers miami collabor develop proprietari point-of-car test use paper strip provid result
page analyst certif import disclosur
get rid
current specif antivir therapi
ifn ribavirin demonstr limit efficaci cov infect
meta-analysi clinic studi convalesc plasma sever acut respiratori infect sari viral etiolog indic therapi
safe may reduc mortal though robust clinic trial need
sera convalesc patient shown neutral infect isol viru vitro
interestingli mild-to-moder patient made full symptomat recoveri report develop antibody-secret cell asc follicular
helper cell tfh cell activ cell cell addit igm igg antibodi specif resolut
symptom least day recoveri studi group suggest character immun paramet could use predict
diseas sever patient ad earli adapt immun respons could correl better clinic outcom
though sever effort discov treatment and/or vaccin novel cov develop
trial on-going sever re-purpos drug exist method includ remdesivir chloroquin favipiravir convalesc plasma tcm among
per who-china report ideal anim model studi rout transmiss pathogenesi antivir therapi vaccin immun
respons yet found transgen mous model macaca rhesu model alreadi use research laboratori
follow slide attempt review program develop
hope comprehens brief manner summar mechan current statu program/drug well on-going
clinic trial
clinic develop space obvious evolv rapidli follow slide repres snapshot landscap
addit follow slide also put togeth excel base tracker let us know youd like copi
page analyst certif import disclosur
small molecul treatment
page analyst certif import disclosur
background mechan
chloroquin cq synthet quinin anti-
inflammatori activ potenti chemosensit
use anti-malari drug sinc mechan
behind chloroquin activ anti-malari still elucid
hydroxychloroquin hcq less toxic hydroxyl version
chloroquin first synthes import differenti
chloroquin hydroxychloroquin prefer regard safeti profil
minim risk retin toxic hcq found less toxic
chloroquin accord mcchesney et al
mechanist agent shown inhibit viral entri post-
entri activ vitro liu et al note elev ph acid
intracellular organel endosomes/lysosom disrupt
could inhibit membran fusion could glycosyl
receptor spike protein
prescrib adult children pregnant women
pain nausea vomit headach side effect
lessen chloroquin taken food
cheap rel easi manufactur
chloroquin current approv use treatment
malaria chemoprophylaxi hydroxychloroquin first approv
us current indic treatment prophylaxi
malaria uncompl malaria due falciparum malaria oval
 vivax well treatment rheumatoid arthriti system
discoid lupu erythematosu dermatolog condit note
hydroxychloroquin well chloroquin known broad-
hcq sulfat tablet place drug shortag list
accord american societi health-system pharmacist separ
fda
base preclin anecdot data agent
recommend treatment sever countri us
hydroxychloroquin prefer agent given superior toler
profil broader avail help guid
dose thought cdc note typic dose regimen
util off-label set includ bid day one daili
day mg bid day one bid day mg bid
day one daili day
suppli potenti use hcq prevent measur
treatment sever gener manufactur announc
ramp-up manufactur suppli product sandoz
novarti commit donat dose end may teva
donat dose end march
dose within month provid dose mid-april
amneal plan produc tablet mid-april
page analyst certif import disclosur
vero cell keyaert et al demonstr chloroquin
effect inhibitor replic sars-cov
primat cell chloroquin show strong antivir activ sars-
cov prophylact therapeut intervent chloroquin
function increas endosom ph interf
glycosyl cellular receptor like angiotensin-convert enzym
natur letter editor wang et al demonstr
chloroquin remdesivir potent block viral infect
low-micromolar concentr rdv um chloroquin
um time-of-addit assay vero cell chloroquin
work entri post-entri stage infect block viral
valu chloroquin vero cell
clinic achiev patient shown plasma
rheumatoid arthriti patient receiv chloroquin
high-throughput assay demonstr chloroquin inhibit viral
replic low-micromolar concentr vero
cell assay also replic previou result show
chloroquin inhibit viral replic sars-cov human coronaviru
hydroxychloroquin shown potent chloroquin
inhibit vero cell pharmacokinet model base
vitro data dose mg twice daili hydroxychloroquin sulfat
given oral follow mainten dose mg given twice daili
day recommend
mous model sars-cov replic chloroquin shown
inact vivo one hypothesi chloroquin reduc
hyperinflammatori respons unabl prevent replic vivo
main driver inflammatori respons suggest
chloroquin might effect reduc diseas progress given
combin agent prevent replic
gao et al recent publish use chloroquin
patient china said chloroquin superior
control treatment inhibit pneumonia shorten diseas
cours howev publish data studi site
difficult come conclus statement
italian group complet clinic trial treat covid-
posit patient chloroquin antibiot azithromycin
demonstr posit result trial small sampl size
promis larger clinic trial need complet
page analyst certif import disclosur
sever clinic studi regist chines clinic trial registri use hydroxychloroquin treat
although result yet publish letter editor liu et al show hcq effect inhibit sars-
infect vitro
summari vitro result
exhibit exhibit show cytotox cq hcq treat vero cell determin assay data show moi
maxim effect concentr cq lower hcq
differ valu statist signific moi moi
exhibit exhibit confirm hcq effect inhibit entri step well post-entri stage also found
upon cq treatment exhibit explor mechan action cq hcq inhibit viru entri co-loc virion earli
endosom ee endolysosom analyz immunofluoresc analysi ifa confoc microscopi quantif analysi
show untreat cell intern virion anti-np red observ earli endosom antigen
ee green virion transport late endosomallysosom protein green contrast treat
cq hcq significantli virion cq hcq detect ee virion
cq hcq found co-loc suggest cq hcq block transport
ee appear requir releas viral genom sars-cov
page analyst certif import disclosur
base abstract publish clinic result chloroquin hydroxychloroquin found effici
chines patient
recent french group led didier raoult complet publish success trial
hcq daili
hcq daili antibiot azithromycin
incid presenc absenc viral load day post inclus nasopharyng swab
patient posit patient
asymptomat upper respiratori tract infect
lower respiratori tract infect patient
treat studi show signific reduct viral load
day post inclus compar control shorter
carriag durat compar untreat patient
literatur azithromycin ad treatment
regimen hydroxychloroquin much effici
elimin viru
summari trial show hydroxychloroquin alon
combin azithromycin effect elimin
compar control
data promis sampl size clinic
trial small studi assess
clinic benefit larger trial necessari confirm
antivir activ hcq azithromycin
page analyst certif import disclosur
chloroquin current evalu trial global also launch multi-countri solidar trial
chloroquin one drug test
chloroquin prevent coronaviru diseas
post-exposur prophylaxi pragmat
antivir treatment confirm case ring
chloroquin chemoprevent close contact cluster
efficaci safeti carrimycin treatment patient
variou combin proteas inhibitor oseltamivir favipiravir
chloroquin treatment random
univers
univers
clinic trial regular tcm syndrom differenti
treatment jiangsu provinc
hydroxychloroquin treatment sever pulmonari
random control pragmat trial evalu antivir
effect chloroquin adult patient infect
efficaci safeti hydroxychloroquin treatment
pneumonia caus hc-ncov
comparison lopinavir/ritonavir hydroxychloroquin
page analyst certif import disclosur
single-blind random control clinic trial chloroquin
phosphat treatment novel coronaviru pneumonia
single-arm clinic trial chloroquin phosphat treatment
evalu efficaci safeti hydroxychloroquin sulfat
comparison phosphat chloroquin mild commen patient
novel coronaviru pneumonia random open-
evalu efficaci safeti hydroxychloroquin sulfat
comparison phosphat chloroquin sever patient novel
cancel investig random double-blind parallel
control trial comparison phosphor chloroquin combin
standard therapi standard therapi mild/common patient
cancel investig random double-blind parallel
control trial comparison phosphor chloroquin combin
standard therapi standard therapi serious/crit ill patient
univers chines
academi
univers chines
academi
univers school
page analyst certif import disclosur
prospect random open-label control clinic studi evalu
prevent effect hydroxychloroquin close contact exposur
novel coronaviru pneumonia
renmin hospit
cancel due lack patient random open-label control trial
efficaci safeti hydroxychloroquin sulfat tablet
treatment patient sever novel coronaviru pneumonia
hospit chongq
cancel due lack patient clinic studi safeti
effect hydroxychloroquin sulfat tablet treatment
patient novel coronaviru pneumonia
cancel due lack patient studi efficaci
hydroxychloroquin mild moder infecti diseas
hospit chongq
hospit chongq
efficaci chloroquin lopinavir/ ritonavir mild/gener novel
efficaci therapeut effect hydroxycholoroquin novel coronaviru
first hospit
prospect open-label multiple-cent studi efficaci
chloroquin phosphat patient novel coronaviru pneumonia
hospit sun yat-sen
therapeut effect hydroxychloroquin novel coronaviru pneumonia
studi efficaci chloroquin patient novel coronaviru
renmin hospit
hospit sun yat sen
page analyst certif import disclosur
clinic trial favipiravir tablet combin chloroquin phosphat
treatment novel coronaviru pneumonia
clinic studi chloroquin phosphat treatment
zhongnan hospit
cancel investig efficaci safeti chloroquin phosphat
inhal combin standard therapi treatment novel
open random control trial chloroquin phosphat
hydroxychloroquin sulfat treatment mild common novel
affili xiamen
cancel investig random double-blind parallel control
trial comparison phosphor chloroquin combin standard
therapi standard therapi mild/common patient novel coronaviru
open random control trial chloroquin phosphat
hydroxychloroquin sulfat treatment sever novel coronaviru
hospit guangzhou
affili xiamen
clinic studi chloroquin phosphat treatment sever novel
zhongnan hospit
singl arm studi explor chloroquin phosphat aerosol inhal
treatment novel coronaviru pneumonia
first hospit
page analyst certif import disclosur
background mechan
current remdesivir approv anywher use
remdesivir phosphoramid prodrug
adenosin analogu like nucleotid analog remdesivir work
inhibit viral replic base work ebola viru drug
shown exert effect delay chain termin
specif incorpor rdv posit caus delay chain
termin predominantli posit
origin develop treatment ebola envelop non-
segment negative-strand rna viru drug show potent
vitro activ though limit clinic impact rct outsid ebola
drug shown broad spectrum antivir activ sever rna
virus includ sars-cov mers-cov
remdesivir evalu clinic trial global
limit avail clinic suppli gilead work work
increas avail suppli rapidli possibl extern
two formul liquid freeze-dri
gilead initi clinic trial world-wide work
global health author fda cdc dhh dod nmpa privat
individu respond pandem appropri
due lack treatment measur remdesivir given patient
emerg treatment compassion use guidelin result
patient suffici determin efficaci safeti
remdesivir clinic trial adequ
page analyst certif import disclosur
vitro sars-cov mers-cov
preclin rdv shown potent inhibit sever type
filoviru low level cytotox
primari human cell cultur experi rdv shown
broad spectrum activ bat-cov prepandem bat-cov
circul contemporari human-cov primari human lung cell
rhesu monkey model ebola warren et al show qd iv
dose day led consist level activ form
blood rdv treatment suppress viral replic
confer protect lethal diseas
larg random control clinic trial result
treatment ebola infect rdv dose regimen follow
load dose pt weigh kg mg/kg pt
cut subsequ mainten dose day
patient kg
murin model mer infect rdv shown reduc
lung viral load improv pulmonari function reduc sever lung
studi rhesu macaqu anim randomli assign
one three group per group control group vehicl treat pre
post inocul prophylact rdv inocul
therapeut rdv inocul anim
dose qd day
prophylact rdv prevent clinic diseas lung lesion
treatment rdv appear decreas viral load time though
studi inhibit viral replic respiratori tissu
prove inferior regimen measur well
decreas mortal rate mortal rate rdv arm vs
arm
said studi author note sever factor could impact
rdv efficaci studi includ death trial
occur within day enrol put rdv
advantag given need on-going dose oppos one bolu
importantli rdv appear safe rel well toler
trial line prior compassion use experi
vitro differ inhibit pattern ebola viru rdrp compar
coronaviru mers-cov indic differ mechan action
therapeut rdv reduc sever clinic diseas reduc
rate sever lung diseas viral replic studi author
note prevent lung lesion happen
therapeut treat anim rare observ nhp
studi antivir mer treatment
anoth studi ran screen anti-vir agent
novel strain show remdesivir chloroquin
potent inhibitor infect lower-molecular concentr
rdv um chloroquin um
page analyst certif import disclosur
studi evalu efficaci safeti remdesivir hospit
studi evalu efficaci safeti remdesivir hospit
adult patient mild moder respiratori diseas
protocol coronaviru diseas remdesivir rdv
research
phase random studi evalu safeti antivir activ
remdesivir particip sever
phase random studi evalu safeti antivir activ
remdesivir particip moder
compar standard treatment
advers event relat treatment use coronaviru
page analyst certif import disclosur
multicent adapt random blind control trial
safeti efficaci investig treatment
hospit adult
multi-centr adapt random trial safeti efficaci
treatment hospit adult
allergi
background mechan
current favipiravir market fujifilm japan avigan
zhejiang hisun pharmaceut china favilavir
favipiravir fpv rna polymeras inhibitor approv influenza
japan favipiravir work similar nucleosid analog inhibit
viral replic inhibit rna-depend rna polymeras rdrp
remind therapi aim inhibit one follow point viru
life-cycle viral entri host cell viral replic viral rna
synthesi favipiravir phosphoribosyl activ form
recogn purin nucleotid rdrp block synthesi
favipiravir origin develop fujifilm influenza also
demonstr efficaci varieti virus includ ebola
follow approv clinic test establish februari initi studi
result two trial shenzhen wuhan publish
safeti teratogen embryotox favipiravir
contraind pregnant lactat women japanes
ministri
potenti best suit prior sever diseas asymptomat
mild moder patient rdrp inhibitor prevent viru
prolifer though protect factor beyond
viru damag induc bodi immun
favipiravir current evalu numer clinic trial global
drug approv test clinic trial china
februari march china daili guardian report
zhang xinmin head china nation center
develop state clinic studi result two trial favipiravir
encourag result third peopl hospit shenzhen
studi zhongnan hospit wuhan univers studi
addit monotherapi favipiravir evalu combin
regimen
page analyst certif import disclosur
favipiravir avigan favilavir current evalu multipl trial global addit includ
potenti treatment control arm anoth studi assess bromhexin hydrochlorid china
favipiravir combin tocilizumab treatment
variou combin proteas inhibitor oseltamivir
favipiravir chloroquin treatment
random control trial favipiravir tablet
combin chloroquin phosphat treatment
random control trial safeti efficaci
favipiravir treatment novel coronaviru pneumonia
poorli respons ritonavir/ritonavir
clinic studi safeti efficaci favipiravir
treatment novel coronaviru pneumonia
random open-label control trial evalu
efficaci safeti baloxavir marboxil favipiravir
lopinavir-ritonavir treatment novel coronaviru
favipiravir versu arbidol random
random control trial efficaci safeti
baloxavir marboxil favipiravir tablet novel coronaviru
pneumonia patient still posit viru
detect current antivir therapi
hospit shenzhen
hospit shenzhen
univers school
zhongnan hospit
affili zhejiang
page analyst certif import disclosur
random open-label control trial efficaci
safeti farpiravir tablet treatment patient
favipiravir patient infect
favipiravir sars-cov-infect patient
japan agenc
medic research
page analyst certif import disclosur
studi ran screen anti-vir agent novel strain high concentr favipiravir requir reduc viral
infect compar remdesivir chloroquin rdv um chloroquin um
author note ebola favipiravir effect protect mice ebola viru although valu vero cell
high
march china daili guardian report zhang xinmin head china nation center biotechnolog develop state
clinic studi result two trial favipiravir encourag
third peopl hospit shenzhen studi open-label non-random studi patient non-sever evalu
fpv interferon ifn inhal lpv/rtv ifn- inhal treat control patient receiv fpv dose day day
mg twice daili day mg twice daili result show shorter time viral clearanc fpv arm median time recoveri
day vs day control well signific improv chest imag measur ct improv rate versu
 safeti fpv arm significantli lower control arm
zhongnan hospit wuhan univers open-label random superior studi moder patient
evalu fpv arbidol patient receiv fpv dose day day mg twice daili day mg twice daili
result patient show rapid improv fpv group includ fever cough respiratori frequenc oxygen day
clinic recoveri rate vs arbidol group howev statist differ observ auxiliari
oxygen therapi non-invasive mechan ventil rate group perform poorli critic patient patient
arbidol group patient fpv group consid clinic recov common ae rais level serum uric acid
common fpv group
also trial on-going japan japanes health ministri sourc per guardian suggest favipiravir effect patient
sever symptom
compani report clinicaltri gov guggenheim secur llc research
page analyst certif import disclosur
prezista darunavir drv prezcobix darunavir cobicistat
background mechan
prezista human immunodefici viru proteas inhibitor
indic treatment infect adult pediatr
patient year age older must co-administ
pharmacokinet booster ritonavir cobicistat
darunavir select inhibit cleavag encod gag-pol
polyprotein infect cell therebi prevent format matur
viru particl initi approv fixed-dos
combin cobi prezcobix approv
announc press releas lack evid
support use darunavir see
mani janssen compound includ darunavir process
evalu in-vitro potenti antivir activ
janssen also provid dvr-base medicin support three clinic
studi china soon data becom avail updat
inform
publish studi darunavir coronaviru includ
sar mer -relat diseas includ vitro studi addit
jnj inform product provid unlik
treatment
press releas march
oral tablet oral suspens
approv us
rel well toler common advers effect least
abdomin pain vomit taken food
treatment-nav treatment-experienc adult patient
darunavir resist associ substitut take
one mg tablet ritonavir mg daili food
janssen clinic pharmacolog evid
support inclus drv/cobicistat treatment guidelin
publish data safeti efficaci
profil drv/cobicistat treatment
addit publish in-vitro studi drv
coronaviru base preliminari unpublish result
previous report in-vitro experi like drv
signific activ administ
approv safe efficaci dose treatment
addit structur analys show interact drv
activ site proteas
page analyst certif import disclosur
prezista darunavir current evalu trial thailand assess whole host antivir therapi effect
erad time week defin erad nasopharyng
prezcobix darunavir cobicistat current evalu trial first one random clinic trial parallel assign across two treatment
arm vs convent treatment exclud darunavir cobicistat trial assess treatment effect virolog clearanc rate throat swab
sputum lower respiratori tract secret day
second trial assess prezcobix darunavir mg cobicistat mg tablet tablet taken qd day combin hydroxychloroquin
tablet taken day day compar arm intervent surveil
variou combin proteas inhibitor oseltamivir favipiravir
chloroquin treatment random control
efficaci safeti darunavir cobicistat treatment
pneumonia caus
treatment mild case chemoprophylaxi contact
prevent epidem
page analyst certif import disclosur
background mechan
umifenovir arbidol hydrochlorid indole-deriv antivir
specif membran fusion inhibitor made moscow-bas
pharmstandard shown entri inhibitor
influenza use outsid unit state treatment influenza
also shown potent activ vitro howev
clinic studi conduct mechan action
umifenovir research sinc respiratori diseas
activ membran fusion inhibitor thought
immunomodul anti-influenza effect specif influenza
group sar inhibit fusion viral lipid membran
cell membran prevent contact entri viru
cell addit interferon-induc action stimul
immun humor cell-medi help phagocytosi
approv us use russia china
adult pediatr influenza patient
rash advis take empti stomach
plasma concentr achiev quickli within hour
hour metabol liver thu
avoid cyp inhibitor macrolid antibiot
presum cheap rel easi manufactur
arbidol current use treat influenza russia china
antivir product arpetol umifenovir list
addit includ one antivir within edit
guidelin
prevent diagnosi treatment novel
coronavirus-induc pneumonia issu nation health commiss
peopl republ china tent treatment
china changjiang daili first report drug potenti inhibit
viru team research zhejiang univers research
drug along darunavir nation health commiss
comment drug effect curb
jiem qu along other seen arbidol effect
varieti coronavirus vitro pharmacodynam absenc
prevent joint control mechan medic materi safeguard
materi safeguard order box drug capsul
per box deliveri hubei provinc
number on-going trial assess use retrospect
case seri wang give insight effect patient
activ arm die vs control arm
also includ control arm trial assess thalidomid along
-interferon methylprednisolon
bromhexin along interferon spray trial assess tradit
chines medicin trial assess carrimycin
page analyst certif import disclosur
placebo control studi china hospit patient assess retrospect jan mani experienc fever cough
patient segment group death given arbidol use china moa inhibit virus-
mediat fusion target membran thu block entri viru cell arbidol use show tendenc improv discharg rate
reduc mortal howev sampl size limit random control trial requir assess efficaci safeti patient infect
retrospect cohort studi compar arbidol lopinavir/ritonavir lpv/r lpv/r patient evalu includ
analysi patient posit activ control patient high overal lung total sever score
treatment day patient nasopharyng specimen neg test rt-pcr activ group vs
monotherapi group day respect coronaviru could detect chest ct scan
improv patient combin group day compar monotherapi group
summari trial show arbidol combin demonstr higher efficaci lopinavir/ritonavir alon sampl size small
studi retrospect design larger studi on-going
januari last diagnos februari
arbidol lopinavir mg /ritonavir mg oral
lopinavir mg /ritonavir mg oral day
neg convers rate date diagnosi day
day whether pneumonia progress improv chest ct day
page analyst certif import disclosur
umifenovir arbidol hcl current evalu trial china addit includ potenti
treatment part treatment control arm four studi conduct china
studi compar efficaci three antivir drug abidol
hydrochlorid oseltamivir lopinavir/ritonavir treatment
studi compar efficaci therapeut scheme abidol
atom treatment pneumonia
clinic studi arbidol hydrochlorid tablet treatment
pneumonia caus novel coronaviru
efficaci lopinavir ritonavir arbidol novel
page analyst certif import disclosur
background mechan
kaletra lopinavir/ritonavir lpv/r antivir often use
antiretrovir medicin treat human immunodefici hiv-
infect adult children day age older
approv manufactur drug fall within
proteas inhibitor class addit ritonavir
combin pill allow greater plasma level concentr
lopinavir maintain inhibit metabol
lopinavir second-gener proteas inhibitor pi viru
report around activ hiv vitro vs
ritonavir
resist given posit
lopinavir bind target differ common resist hiv
proteas gene use patient develop resist
pi
approv us treat infect part
nausea vomit hypertriglyceridemia hypercholesterolemia
taken without regard food
similar antivir recommend taken
medic mediat case induc
 dexamethason carbamazepin phenytoin rifampin
gener avail thu presum cheap rel
easi manufactur
chines health author request late januari suppli
aluvia lopinavir/ritonavir part
govern broader effort
address coronaviru crisi china thu made donat
aluvia experiment option support grow public health
crisi addit support research combin drug
european health author fda food drug administr
cdc center diseas control prevent nih nation institut
barda biomed advanc research develop
expect shortag suppli drug hiv patient
continu monitor on-going manufactur
result
suppli chain result
anticip suppli
viru
trial failur china assess therapi sever covid-
addit test chines patient found
receiv treatment better outcom receiv
standard care detail publish new england journal medicin
lopinavir hiv proteas inhibitor report activ
unclear whether inhibitor hiv proteas
aspart proteas famili effect inhibit
cystein proteas famili use base larg trial
sever acut respiratori syndrom sar suggest lopinavir
associ improv clinic outcom mortal
sourc uptod adisinsight press releas file packag insert
page analyst certif import disclosur
vitro parallel antivir activ assay cell recombin mers-cov engin express report nanoluciferas compar anti-vir activ
agent
remdesivir show potent inhibit mers-cov replic
observ cytotox
highli select compar activ
arm miracl trial antivir activ lopinavir
ritonavir combin similar
lopinavir alon
suggest lopinavir major driver activ
combin assay data demonstr remdesivir
 superior vitro antivir activ compar
kaletra combin drug ritonavir
significantli enhanc antivir activ lopinavir vitro
sever detail report clinic experi lopinavir publish though data encourag studi patient
singapor receiv lopinavir/ritonavir clinic benefit differenti diseas progress howev lower dose
use mg oral bid vs qd bid per label lopinavir/ritonavir anoth studi patient shanghai mild diseas
sever diseas receiv lopinavir/ritonavir mg oral bid day along treatment includ arbidol tradit
chines medicin tcm patient improv neg viral test end data collect last patient sever
show sign improv end data collect
recent nejm publish studi patient evalu lopinavirritonavir vs standard care percentag patient detect rna time
similar differ observ time clinic improv hr mortal rate day similar arm
activ arm vs standard care studi author conclud treatment benefit observ
infecti diseas alert pharmacotherapi consider sheahan tp commun jan
page analyst certif import disclosur
kaletra lopinavir/ritonavir involv trial global includ trial part control arm
evalu trial global addit trial china attempt retracted/cancel clinicaltri gov
captur follow
comparison lopinavir/ritonavir hydroxychloroquin patient
prospective/retrospect random control clinic studi
antivir therapi pneumonia
deem high import
evalu compar safeti effici
lopinavir/ritonavir novel coronaviru infect
efficaci lopinavir ritonavir arbidol novel
trial treatment hospit adult
lopinavir/ ritonavir ribavirin ifn-beta combin ncov
variou combin proteas inhibitor oseltamivir favipiravir
chloroquin treatment random control trial
mers-cov infect treat combin lopinavir /ritonavir
interferon
hospit zhejiang
nation institut
medic
univers
page analyst certif import disclosur
background mechan
current data regard use oseltamivir ncov
thu case report use on-going clinic trial
like share insight cover next slide
single-cent case seri hospit patient confirm
ncip wuhan china presum hospital-rel transmiss
ncov suspect patient patient receiv icu care
mortal hospit patient
receiv oseltamivir februari patient discharg
die overal mortal remain patient still
hospit among discharg aliv median hospit
stay day iqr
watch result prospect open-label
random multicent studi thailand stratifi sever
look mild diseas
tamiflu oseltamivir influenza neuraminidas inhibitor nai
indic treatment acut uncompl influenza
patient week older symptomat
hour also use prophylact manag influenza
 patient year older
manufactur genentech/rog-swx
approv us who list essenti medicin
vomit headach pain taken without regard food
avail capsul formul powder oral
adult older year recommend
dose bid day
given
presum cheap rel easi manufactur
product approv gener
page analyst certif import disclosur
tamiflu oseltamivir involv trial global includ trial part control arm evalu
variou combin proteas inhibitor oseltamivir favipiravir
chloroquin treatment random control trial
prospective/retrospect random control clinic studi
antivir therapi pneumonia
page analyst certif import disclosur
background mechan
clinic trial small sampl size assess oral
ganovo ritonavir combin therapi led dr hongyi
chen director ninth hospit nanchang obtain approv
ethic committe hospit februari
one treatment group studi group receiv oral ganovo
ritonavir combin therapi novel coronaviru pneumonia
patient plan enrol patient actual enrol
patient receiv oral ganovo ritonavir combin therapi
discharg satisfi discharg standard
diagnosi treatment program novel coronaviru
infect trial version issu nation health commiss
peopl republ china
danoprevir oral avail second-gener non-coval
small-molecul revers inhibitor hepat viru hcv
proteas origin array biopharma subsidiari
intermun subsidiari roch rog-swx
later sold roch
oral formul approv avail hcv infect china
clinic develop indic underway sever
rog-swx also develop fixed-dos combin fdc tablet
ritonavir-boost danoprevir treatment hepat
ganovo first direct-act antivir agent daa develop
domest compani china approv june treat viral
hepat develop ascleti subsidiari wuxi apptec
chines biotech ascleti pharma announc march
progress small sampl clinic trial hepat treatment ganovo
danoprevir ritonavir combin therapi novel coronaviru
ascleti license china believ danoprevir combin
ravidasvir may offer effect interferon-fre regimen treatment
hcv clinic develop regimen underway taiwan
china infect
page analyst certif import disclosur
ganovo danoprevir itmn current evalu trial china
combin ritonavir with/without interferon spray inhal
trial random clinic trial parallel assign across treatment arm assess rate composit advers outcom
day defin without oxygen supplement respiratori rate breath per minut without
recombin cytokin gene-deriv protein spray inhal novaferon
open control clinic trial evalu ganovo
danoprevir combin ritonavir treatment
ninth hospit
page analyst certif import disclosur
background mechan
xofluza baloxavir marboxil polymeras acid pa cap-
recent approv select inhibitor influenza cap-
depend endonucleas essenti enzym viral replic hayden
et al although baloxavir found potent activ
varieti influenza virus variant influenza amino acid
substitut posit polymeras acid protein
produc higher baloxavir vitro incid
treatment-emerg substitut variant adult
xofluza pediatric-focus studi show rel higher
frequenc takashita et al
manufactur genentech/rog-swx
approv us treatment acut uncompl
influenza patient year older
symptomat hour otherwis
healthi high risk develop influenza-rel
bronchiti nausea sinus headach
taken without regard food
patient weigh recommend dose two
mg tablet taken within hour symptom onset
current data publicli avail regard xofluza efficaci
howev trial china along favipiravir
cover later
cipla partnership council scientif industri research-
indian institut chemic technolog scale stockpil antivir
compound favipiravir remdesivir baloxavir
trial conduct influenza includ capston studi capstone-
phase trial otherwis healthi patient year old
uncompl influenza demonstr baloxavir significantli reduc
viral titer time allevi symptom tta compar
placebo clinic benefit baloxavir observ regardless
variant statu hayden et al clear
associ emerg variant exacerb
phase trial high-risk patient uncompl
influenza demonstr baloxavir well-toler
associ faster recoveri reduc risk complic high-risk
influenza patient compar placebo baloxavir superior
oseltamivir shorten durat viral shed influenza
 viru resolv influenza b-associ ill ison et al
variant found patient enrol
studi emerg result longer time
improv influenza symptom portsmouth
page analyst certif import disclosur
xofluza baloxavir marboxil current evalu china two random clinic trial parallel
assign across treatment arm activ control assess baloxavir marboxil favipiravir one
trial evalu combin backbon current antivir treatment compar
treatment lopinavir/ritonavir
random control trial efficaci safeti baloxavir
marboxil favipiravir tablet novel coronaviru pneumonia
patient still posit viru detect
current antivir therapi
random open-label control trial evalu efficaci
safeti baloxavir marboxil favipiravir lopinavir-ritonavir
treatment novel coronaviru pneumonia
affili
school
page analyst certif import disclosur
background mechan
ascleti pharma asclf compani hong kong said receiv
approv clinic trial fixed-dos combin ritonavir
treat coronaviru pneumonia upon review
current two clinic trial on-going china expect
primari complet date may thu would expect result
efficaci safeti
evalu trial china addit trial retract due
lack patient
evalu compar safeti effici
lopinavir/ritonavir novel coronaviru
zhejiang univers
random open control clinic studi evalu
efficaci ritonavir pneumonia
page analyst certif import disclosur
enanta pharma announc march initi
two-prong approach effort
drug discoveri program leverag experi
direct-act antivir drug mechan candid along
secondli compani also screen compound antivir
compound librari potenti activ
experi develop antivir drug collabor
glecaprevir proteas inhibitor discov
current market mavyret treatment chronic hcv
compani addit work discoveri anoth direct-
act antivir compound pibrentasvir part fixed-dos
combin drug mavyret glecaprevir
page analyst certif import disclosur
vaccin treatment
page analyst certif import disclosur
recal central dogma biolog hard code genet inform dna transcrib transport temporari cassett known messeng rna
mrna mrna cassett contain recip synthesi particular protein small number protein mrna-bas vaccin approach mimic
immun respons induc mrna encod protein also util bodi biolog self-manufactur vaccin thu share
pharmacolog endogen mrna instead manufactur larg amount protein factori provid dose patient mrna given
subject use templat bodi essenti self-vaccin
mrna code protein degrad variou pathway either amino acid antigen peptid epitop induc virus-specif cell respons
degrad antigen peptid epitop load onto major histocompat complex mhc molecul express surfac healthi cell mark
cell self vs foreign mhc express protein-deriv epitop cell surfac gener immun respons
benefit mrna-bas vaccin
current approv mrna-bas therapi use vaccin otherwis howev anim model encourag show
immun dose multipl mrna-bas vaccin develop
recal protein degrad antigen peptid epitop induc virus-specif cell respons three approach current
clinic mrna encod combin viral protein two compon vaccin contain mrna adjuv mrna encod antigen self-
amplifi mrna sequenc positive-strand rna virus
mrna vaccin made faster timescal compar convent vaccin product week instead month mrna produc use
use cell-fre system without cellular anim compon involv howev mrna-bas medicin new without approv
commerci product manufactur capabl may vari depend manufactur
treci et al mrna-bas therapeut -- develop new class drug compani report guggenheim secur llc research
page analyst certif import disclosur
background mechan
mrna-bas vaccin develop
candid encod full-length prefus stabil form spike
protein encapsul lipid nanoparticl
moderna mrna vaccin platform includ prophylact vaccin
develop vaccin candid demonstr posit phase
readout prophylact vaccin rsv chikungunya
viru cmv latest stage vaccin program cmv
program phase studi
mrna/nih previous collabor vaccin mer
remain research stage
inject phase studi evalu dose cohort
microgram mcg mcg patient receiv two dose
deltoid day apart
state produc million dose per year
built operation intern fulli integr sq ft
norwood facil month scale product
manufactur million dose per month potenti form individu
multi-dos vial
current evalu phase studi
healthi adult
mrna vaccin design manufactur day nih
final sequenc jan day chines govern
releas sequenc follow began manufactur first
clinic batch complet feb ship nih feb
fda complet ind review march first patient
dose phase trial march full develop timelin
avail mrna websit
nih conduct preclin test mice yet publish
show potent antibodi respons emphas phase test
base safeti assess base prior human studi
mrna-bas vaccin addit anim studi mice nhp
addit data phase underway establish
rational test vaccin larger trial warrant niaid
phase studi expect enrol healthi adult week
studi enrol patient kaiser permanent washington
research institut seattl jennif hall first patient inject
see time interview march kaiser permanent note
studi recruit close
prepar potenti phase studi ind
could begin month manufactur alreadi underway
competitor confer march ceo bancel describ
month timelin commercially-avail vaccin potenti
earlier emerg vaccin avail peopl healthcar
profession fall
compani report clinicaltri gov guggenheim secur llc research
page analyst certif import disclosur
current develop candid prophylact vaccin modal includ respiratori virus includ two pandem
influenza strain rsv hmpv infect transmit mother-to-babi includ cmv zika highli preval viral infect
ebv compani dose healthi volunt phase vaccin trial dose level safeti toler profil
appear consist market adjuv vaccin
demonstr posit phase data readout measur neutral antibodi viral antigen prophylact vaccin
rsv chikungunya viru cmv initi zika vaccin instead compani advanc mrna-
next-gen zika vaccin
mrna/nih previous collabor vaccin mer
anoth speci coronaviru similar mer also
contain spike protein complex necessari membran fusion
host cell infect collabor nih design
mrna-bas vaccin target prefusion-stabil spike protein
mer rabbit model vaccin led induct nab
result reduct viral titer nose reduct
viral titer detect bronchoalveolar lavag viral titer throat
reduc lower limit detect
compani report clinicaltri gov guggenheim secur llc research
page analyst certif import disclosur
background mechan
curevac develop mrna-bas vaccin collabor
duke-nu develop coronaviru vaccin curevac
mrna-bas vaccin focu optim utr orf chemistri
maintain unmodifi nucleosid vaccin encapsul
detail vaccin light compani
vaccin program on-going includ clinical-stag rabi program
preclin stage influenza program result phase studi
evalu rabi vaccin healthi volunt show
immun respons lowest dose cohort
curevac product suit tbingen germani includ
gmp qualif suit suit construct
compani note build capac produc million dose
rna-bas therapeut per year curevac state
produc ten million vaccin dose one product run note
work expand manufactur capac abl
provid billion dose outbreak situat like
addit compani rna printer capabl produc sever
gram lnp-formul mrna enough produc hundr
thousand dose within week
curevac mrna vaccin current preclin stage develop
curevac current select candid sever construct
note work acceler develop german paul
ehrlich institut european health author compani
expect start clinic trial earli summer
compani note march confer call replay
two vaccin candid await anim data
compani report clinicaltri gov guggenheim secur llc research
page analyst certif import disclosur
curevac lead vaccin program vaccin rabi
legaci report result gen program
util optim mrna technolog optim utr orf formul
lipid nanoparticl
result gen program
curevac conduct phase studi healthi volunt
rabi vaccin healthi volunt receiv
 dose three time either needle-syring needle-fre
devic either intraderm intra-muscularli result publish
lancet show patient dose needle-fre devic
demonstr neutral antibodi titer iu/ml
particip given dose intraderm
six particip given dose
intramuscularli needle-syring inject show effect
particip intraderm show detect immun
result gen program
evalu phase studi
healthi volunt open-label dose-escal studi origin
design evalu intramuscular dose vaccin day
dose level januari curevac report interim result
lowest dose cohort two dose mrna vaccin
induc adapt immun respons virus-neutr antibodi
titer who recommend threshold result
expect scientif confer
curevac develop gen lnp influenza vaccin
compani complet nhp studi compani note
demonstr strong durabl immunogen non-human primat
addit inform avail
curevac coalit epidem prepared innov cepi
enter partnership februari develop lnp
mrna-bas vaccin known pathogen new previous
develop vaccin lassa fever rabi yellow fever
partnership expand januari develop vaccin covid-
melinda gate foundat
melinda gate foundat made initi million equiti
invest march develop mrna-bas vaccin
foundat award addit grant februari
develop prophylact vaccin influenza malaria infect
compani report clinicaltri gov guggenheim secur llc research
page analyst certif import disclosur
background mechan
current preclin stage develop
develop mrna-bas vaccin
develop induc immun prevent coronaviru
infect compani partner fosun pharma develop
china co-develop ex-china region
nucleosid modifi mrna self-amplifi mrna sarna
trans-amplifi mrna tarna weve discuss detail
pubm pregam seri compani use modifi mrna
mrna approach compani specifi detail around
bntx vaccin portfolio also includ influenza partnership
partnership penn drew weissman agreement
melinda gate foundat develop vaccin hiv tuberculosi
bntx disclos mrna format
note util sarna platform potenti
allow higher respons lower dose
btnx respons manufactur compani
facil support discoveri formul gmp manufactur
current preclin stage develop compani
expect begin clinic test late april
compani note contact global regulatori agenc
plan global clinic develop program europ
commenc germani unit state china
bntx/pfe note plan util multipl research
develop site compani includ unit state
germani hous activ identifi collabor agreement
bntx fosun pharma jointli conduct clinic trial china upon
regulatori approv fosun pharma commerci vaccin china
compani report clinicaltri gov guggenheim secur llc research
page analyst certif import disclosur
highlight sever mrna format could util
optim uridin mrna urna urna optim
immunogen optim uridin activ immun sensor
modifi nucleosid reduc immunogen reaction
self-amplifi mrna sarna sarna encod protein interest
like convent mrna well replicas polymeras
multipli mrna within target cell allow higher level
sustain antigen product lower dose
trans-amplifi mrna tarna tarna divid job sarna
two piec vaccin antigen replicas compon
co-develop mrna-bas vaccin
influenza bntx enter collabor agreement august
encod influenza viru antigen select
advanc flu season util bntx self-amplifi mrna
platform encapsul lnp program current preclin
develop compani expect begin clinic develop
univers pennsylvania drew weissman lab
enter partnership novemb develop
nucleoside-modifi mrna-bas vaccin diseas candid
respons discoveri complet ind-
enabl studi bntx option licens
candid compani expect begin first phase studi
melinda gate foundat
bntx melinda gate foundat enter agreement
develop mrna-bas vaccin hiv tuberculosi septemb
includ initi equiti invest
compani report clinicaltri gov guggenheim secur llc research
page analyst certif import disclosur
background mechan
arct mrna vaccin current preclin develop
arct develop mrna-bas vaccin collabor
duke-nu develop coronaviru vaccin vaccin
util starr self-transcrib replic rna encod
antigen also viral replic machineri replicas
polymeras allow high antigen product low dose vaccin
arct manag indic base pre-clin work starr
technolog dose multipl fold lower dose mrna-
base vaccin given sustain express seen mice
potenti booster dose would need
arct experi develop vaccin partnership
includ undisclos partnership vaccin compani relat
anim health compani person cancer vaccin partnership
starr platform arct self-repl mrna encod protein
interest like convent mrna also encod replicas
polymeras multipli mrna within target cell
produc double-strand rna intermedi trigger
immun respons small level initi mrna
microgram dose arct note expect dose singl
microgram dose rang potenti booster would
arct state produc doubl digit gram drug substanc
less week given singl microgram dose believ singl
batch pend dosing/tri could potenti vaccin whole
arct mrna vaccin current preclin develop
call arct note compani alreadi chosen target
vaccin program process development/scal
provid materi singaporean govern initi test
dr ooi eng eong deputi director duke-nuss emerg infecti
diseas program comment reuter articl publish march
mice studi would start week human clinic trial
expect
compani report clinicaltri gov guggenheim secur llc research
page analyst certif import disclosur
background mechan
fudan univers shanghai jiaotang univers rnacur
collabor develop mrna-bas vaccin group
announc joint research collabor march plan
use two method use mrna express receptor-bind spike
protein induc nab use mrna produc virus-
like particl vlp featur morpholog structur similar
virus activ immun respons group note
focus option given similar efficaci vlp
live attenu virus optim safeti profil group
formul mrna cocktail contain three gene
fudan univers shanghai jiaotang univers rnacur mrna-
base vaccin preclin develop
mrna cocktail contain gene produc
fudan univers shanghai jiaotang univers rnacur mrna-
base vaccin preclin develop
addit detail around program disclos
knowledg
compani report clinicaltri gov guggenheim secur llc research
page analyst certif import disclosur
mrna vaccin chines centr diseas control prevent
tongji univers school medicin
background mechan
chines centr diseas control prevent tongji
univers school medicin stermirna therapeut
develop mrna-bas vaccin program announc
januari current preclin develop stermirna ceo
li hangwen state day need
manufactur vaccin sampl base new gener mrna
technolog preliminari procedur
mrna vaccin current preclin develop
detail around program disclos
mrna vaccin current preclin develop initi mice
test began februari per xinhua group plan conduct
studi larger anim model prior clinic test clinic test
interview thepap cn stermirna chief execut li hangwen
note vaccin could arriv market first-phas
compani report clinicaltri gov guggenheim secur llc research
page analyst certif import disclosur
background mechan
self-amplifi rna sa-rna vaccin deriv alphavirus
positive-strand non-seg rna virus rna vaccin
demonstr versatil mani anim model infecti non-
infecti diseas self-amplifi rna replicon encod gene drive
amplif within cytoplasm host cell sa-rna vaccin
potenti effect correspond mrna vaccin
compar rapid express convent mrna publish
result shown vaccin self-amplifi mrna vaccin
result higher antigen express level although delay time
persist sever day vivo
shattock lab self-amplifi rna vaccin approv
anywher use
clinic trial mrna vaccin infecti diseas earli
stage trial conduct mrna encod antigen
human cytomegaloviru shown safeti antigen-specif immun
self-amplifi rna vaccin evalu
coronavirus preclin clinic studi
administ nake rna packag viral particl deliv
electropor situ
safeti less risk integr genom immun host
dna vaccin
directli translat cytoplasm need nuclear deliveri
challeng deliveri rna vaccin particularli
potenti wide use prophylact coronaviru infect
professor robin shattock team imperi colleg london
depart infecti diseas develop candid vaccin within
day get sequenc china
lab began test vaccin anim februari plan
move clinic trial summer
shattock lab vaccin current evalu
clinic trial
page analyst certif import disclosur
background mechan
modifi vaccinia ankara mva vaccin consid safe
vaccin platform advantag live replication-compet
vector avian cell manufactur replication-defici
mammalian cell vaccin importantli mva vaccin elicit protect
cell well antibodi respons anim human
viru like particl vlp use express protein nativ
conform enabl construct immunogen vaccin candid
induc full protect singl dose live viru
involv manufactur process vlp easili gener
mva vaccin platform use commerci avail jynneo
smallpox vaccin use numer preclin clinic trial
vaccin vector sever infecti diseas includ mers-
cov zika
sever vlp-base vaccin commerci avail includ vaccin
human papilloma viru hpv cervarix gardasil
hepat viru hbv includ gener sci-b-
addit first licens malaria-vlp-bas vaccin mosquirix
approv european regul
jynneo mva vaccin administ subcutan inject
advantag includ safeti proven clinic efficaci vaccin
platform mers-cov
disadvantag includ mva vaccin yet approv
prevent coronavir infect
advantag includ safeti due inabl replic well
proven abil elicit strong cell cell immun respons
vlp technolog appli sever approv vaccin
includ blockbust gardasil gardasil hbv vaccin
disadvantag express system may limit
effect vlp vlp yet approv
prevent coronavir infect
januari geovax bravovax sign letter intent
jointli develop vaccin
geovax use mva-vlp vaccin platform design construct
vaccin candid use genet sequenc on-going coronaviru
outbreak origin wuhan china bravovax provid
develop includ test manufactur support well direct
interact chines public health regulatori author
mva-vlp current evalu clinic trial
page analyst certif import disclosur
